• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性复发性深静脉血栓形成患者循环组织因子阳性微粒。

Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis.

机构信息

Department of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

出版信息

Thromb Res. 2012 Aug;130(2):253-8. doi: 10.1016/j.thromres.2011.10.014. Epub 2011 Nov 17.

DOI:10.1016/j.thromres.2011.10.014
PMID:22099707
Abstract

INTRODUCTION

Circulating tissue factor positive microparticles (MPTF) were reported in a wide range of diseases with thrombotic tendency. Though D-dimer assay had a high negative predictive value for deep venous thrombosis (DVT) recurrence, there are currently no reliable positive predictors for recurrent DVT. We therefore quantified MPTF in patients with acute recurrent DVT to determine whether MPTF levels could be used to predict recurrent DVT.

MATERIALS AND METHODS

Microparticles (MPs) were isolated from plasma of initial DVT patients (n=25), recurrent DVT patients (n=25) and sex- and age-matched healthy individuals (n=25), stained with annexin V, cell-specific monoclonal antibodies (MoAbs) and a MoAb directed against tissue factor (TF), and analyzed by flow cytometry. We also determined the plasma procoagulant activity with a Human TF Chromogenic Activity Assay Kit.

RESULTS

We found total MPTF to be elevated in recurrent DVT patients versus normal individuals (P=0.001). The number of monocyte-derived MPTF in both initial and recurrent DVT was higher than in normal individuals (P<0.01, respectively). The platelet and endothelial cell derived MPTF in recurrent DVT were significantly increased relative to other MPTF (P<0.05), although there was no difference between initial DVT patients and normal individuals. We demonstrated elevated procoagulant activity of platelet-free plasma in DVT patients relative to normal individuals, and a positive correlation with MPTF.

CONCLUSIONS

The elevated MPTF could be a potentially predictor for DVT recurrence. Further studies are needed to validate its sensitivity and specificity.

摘要

简介

循环组织因子阳性微粒(MPTF)在多种具有血栓倾向的疾病中均有报道。尽管 D-二聚体检测对深静脉血栓(DVT)复发具有很高的阴性预测值,但目前尚无可靠的阳性预测因子用于预测复发性 DVT。因此,我们对急性复发性 DVT 患者进行了 MPTF 定量检测,以确定 MPTF 水平是否可用于预测复发性 DVT。

材料和方法

从初发 DVT 患者(n=25)、复发性 DVT 患者(n=25)和性别及年龄匹配的健康个体(n=25)的血浆中分离出微粒(MPs),用 Annexin V、细胞特异性单克隆抗体(MoAb)和针对组织因子(TF)的 MoAb 进行染色,并用流式细胞术进行分析。我们还使用 Human TF 显色活性检测试剂盒测定了血浆促凝血活性。

结果

我们发现复发性 DVT 患者的总 MPTF 高于正常个体(P=0.001)。初发和复发性 DVT 患者的单核细胞衍生 MPTF 数量均高于正常个体(P<0.01)。复发性 DVT 患者的血小板和内皮细胞衍生 MPTF 明显高于其他 MPTF(P<0.05),而初发 DVT 患者与正常个体之间无差异。我们证明了 DVT 患者无血小板血浆的促凝血活性相对于正常个体升高,且与 MPTF 呈正相关。

结论

升高的 MPTF 可能是 DVT 复发的潜在预测因子。需要进一步的研究来验证其敏感性和特异性。

相似文献

1
Circulating tissue factor positive microparticles in patients with acute recurrent deep venous thrombosis.急性复发性深静脉血栓形成患者循环组织因子阳性微粒。
Thromb Res. 2012 Aug;130(2):253-8. doi: 10.1016/j.thromres.2011.10.014. Epub 2011 Nov 17.
2
Microparticle-associated tissue factor activity in patients with acute unprovoked deep vein thrombosis and during the course of one year.急性特发性深静脉血栓形成患者及随访一年期间微粒相关组织因子活性
Thromb Res. 2014 Nov;134(5):1093-6. doi: 10.1016/j.thromres.2014.07.041. Epub 2014 Aug 22.
3
Monocytes and plasma tissue factor levels in normal individuals and patients with deep venous thrombosis of the lower limbs: potential diagnostic tools?正常个体及下肢深静脉血栓形成患者的单核细胞和血浆组织因子水平:潜在的诊断工具?
Thromb Res. 2007;119(2):157-65. doi: 10.1016/j.thromres.2006.01.005. Epub 2006 Mar 9.
4
Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer.血浆微粒体中组织因子促凝活性在早期前列腺癌患者中增加。
Thromb Haemost. 2009 Jun;101(6):1147-55.
5
Microvesicles as risk markers for venous thrombosis.微囊泡作为静脉血栓形成的风险标志物。
Expert Rev Hematol. 2013 Feb;6(1):91-101. doi: 10.1586/ehm.12.74.
6
Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism.伴有和不伴有静脉血栓栓塞症的癌症患者中的内皮细胞、血小板和组织因子载带的微粒。
Thromb Res. 2011 May;127(5):473-7. doi: 10.1016/j.thromres.2011.01.002. Epub 2011 Jan 22.
7
Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb.下肢急性深静脉血栓形成后可溶性 P 选择素、D-二聚体和高敏 C 反应蛋白。
J Vasc Surg. 2011 Dec;54(6 Suppl):48S-55S. doi: 10.1016/j.jvs.2011.05.097. Epub 2011 Sep 3.
8
Circulating tissue factor and microparticles are not increased in patients with deep vein thrombosis.深静脉血栓形成患者的循环组织因子和微粒并未增加。
Vasa. 2011 Mar;40(2):117-22. doi: 10.1024/0301-1526/a000081.
9
Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice.循环癌细胞衍生微粒所表达的组织因子会大幅增加小鼠深静脉血栓形成的发生率。
J Thromb Haemost. 2015 Jul;13(7):1310-9. doi: 10.1111/jth.13002. Epub 2015 Jun 8.
10
Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations.抗磷脂抗体患者循环中的微粒:特征与关联
Thromb Res. 2015 Jan;135(1):102-8. doi: 10.1016/j.thromres.2014.11.011. Epub 2014 Nov 15.

引用本文的文献

1
Challenges with measuring tissue factor antigen and activity in human plasma.测量人血浆中组织因子抗原和活性的挑战。
Blood Vessel Thromb Hemost. 2024 Jul 31;1(4):100022. doi: 10.1016/j.bvth.2024.100022. eCollection 2024 Dec.
2
Research into New Molecular Mechanisms in Thrombotic Diseases Paves the Way for Innovative Therapeutic Approaches.血栓性疾病新分子机制的研究为创新治疗方法铺平了道路。
Int J Mol Sci. 2024 Feb 21;25(5):2523. doi: 10.3390/ijms25052523.
3
Monoclonal Gammopathy of Thrombotic Significance.具有血栓形成意义的单克隆丙种球蛋白病
Cancers (Basel). 2023 Jan 12;15(2):480. doi: 10.3390/cancers15020480.
4
Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma.多发性骨髓瘤血栓并发症的当代风险评估、预防及管理方法
Cancers (Basel). 2022 Dec 16;14(24):6216. doi: 10.3390/cancers14246216.
5
Plasma procoagulant phospholipid clotting time and venous thromboembolism risk.血浆促凝磷脂凝血时间与静脉血栓栓塞风险
Res Pract Thromb Haemost. 2021 Dec 20;5(8):e12640. doi: 10.1002/rth2.12640. eCollection 2021 Dec.
6
Extracellular Vesicles and Thrombosis: Update on the Clinical and Experimental Evidence.细胞外囊泡与血栓形成:临床与实验研究进展。
Int J Mol Sci. 2021 Aug 27;22(17):9317. doi: 10.3390/ijms22179317.
7
Extracellular vesicles as potential biomarkers and therapeutic approaches in autoimmune diseases.细胞外囊泡作为自身免疫性疾病的潜在生物标志物和治疗方法。
J Transl Med. 2020 Nov 12;18(1):432. doi: 10.1186/s12967-020-02609-0.
8
The role of bone marrow-derived cells in venous thromboembolism.骨髓源性细胞在静脉血栓栓塞中的作用。
Int J Biochem Cell Biol. 2020 Nov;128:105850. doi: 10.1016/j.biocel.2020.105850. Epub 2020 Sep 17.
9
Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.接受化疗的结直肠癌患者中微粒、凝血酶 - 抗凝血酶复合物及血管内皮生长因子水平升高
Pathol Oncol Res. 2020 Oct;26(4):2499-2507. doi: 10.1007/s12253-020-00854-8. Epub 2020 Jun 24.
10
Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.预测复发性静脉血栓栓塞的风险:当前挑战与未来机遇
J Clin Med. 2020 May 22;9(5):1582. doi: 10.3390/jcm9051582.